{"url_path":"/sec/snse/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-234882-index.html","accession_number":"0001193125-26-234882","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-234882-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":94,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \n\nExhibit Description\n\n99.1\n  \n[Unaudited Pro Forma Condensed Financial Information of Sensei Biotherapeutics, Inc. for the quarter ended March 31, 2026.](d162035dex991.htm)\n\n104\n  \nThe cover page from this Current Report on Form 8-K, formatted in Inline XBRL\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nSensei Biotherapeutics, Inc.\n\nDate: May 21, 2026\n \n\n \n\n \n\n/s/ Christopher W. Gerry\n\n \n\n \n\n \nChristopher W. Gerry\n\n \n\n \n\n \nPresident and General Counsel"}